| 000 | 01752cam a2200325 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223031747.0 | ||
| 008 | 170729s2015 ua f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aGift | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.34.Ph.D.2015.No.D | ||
| 100 | 0 | _aNoha Ahmed Abdelaziz Mohamed Osman | |
| 245 | 1 | 0 |
_aDesign and synthesis on novel cannabinoid receptor ligands / _cNoha Ahmed Abdelaziz Mohamed Osman ; Supervised Ashraf H. Abadi , Khaled A. Abouzid |
| 246 | 1 | 5 | _aتصميم و تشييد لبعض المركبات الجديدة لمستقبلات الاندوكنابينويد |
| 260 |
_aCairo : _bNoha Ahmed Abdelaziz Mohamed Osman , _c2015 |
||
| 300 |
_a173 Leaves ; _c30cm |
||
| 502 | _aThesis (Ph.D.) - German University - Faculty of Postgraduate Studies and Scientific Research - Department of Pharmaceulical Chemistry | ||
| 520 | _aCannabinoid receptor endocannabinoids and enzymes catalyzing their formation and degradation coflectively constitute the endocannabinoid system. The potential modulation of this system for therapeutic gain has become a central focus of research during the last decade. Two cannabinoid receptor subtypes (CB1) and CB2) have been identified, which have variable tissue distribution. The CB1 subtype is mainly localised in the CNS and is the subtype that mediates the psychotropic effects of A⁹-THC | ||
| 653 | 4 | _aCannabinoid receptor | |
| 653 | 4 | _aEndocannabinoids | |
| 653 | 4 | _aEnzymes catalyzing | |
| 700 | 0 |
_aAshraf H. Abadi , _eSupervisor |
|
| 700 | 0 |
_aKhaled A. Abouzid , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c61687 _d61687 |
||